Analysis of immune-related dermal toxicity identified that a baseline Systemic Immune-Inflammation Index (SII) ≥660 (OR = 8.742, 95% CI = 1.372-55.648, P = 0.022) and CD4<sup>+</sup>PD-1<sup>+</sup> >42.10% (OR = 18.121, 95% CI = 1.368-239.948, P = 0.028) were independent risk factors, whereas IL-17 >21.4 pg/mL (OR = 0.042, 95% CI = 0.003-0.542, P = 0.015) was an independent protective factor.<h4>Conclusions</h4>In this real-world cohort, cadonilimab showed promising early efficacy and a manageable safety profile in cervical cancer. This evidence concerns the gene IL17A and cervical carcinoma.